Recent News

The findings could pave the way toward more targeted treatments for the disease.

At Memorial Sloan Kettering Cancer Center’s 43rd annual event recognizing graduates and award winners, honorees were welcomed back to an in-person event.

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.

The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.

The pictures provide new clues about how the androgen receptor interacts with cancer-causing proteins.

Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation. The program will support the visionary work of scientists at the Sloan Kettering Institute (SKI), the research arm of MSK, by funding foundational laboratory research that will drive the next generation of cancer breakthroughs and ultimately improve the lives of people facing cancer around the world.

The in-person event featured scientific talks from leading women in science, including winners of this year’s Kravis WiSE fellowships.

Topics included more diverse representation in clinical trials, racial disparities in colorectal cancer, and ancestry testing to improve diagnoses.